USP Initiatives for the Safe Use of Medical Gases - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

USP Initiatives for the Safe Use of Medical Gases
USP's Medication Errors Reporting Program has become aware of increasing medical gas errors. Working with interested parties, USP is revising monographs in USP–NF to help minimize the risk of these errors

Pharmaceutical Technology
Volume 29, Issue 11

Medical gases (e.g., oxygen, carbon dioxide, helium, nitrogen, nitrous oxide, medical air, and combinations of these) are drugs regulated by section 201(g) of the Federal Food, Drug, and Cosmetic Act. The United States Pharmacopeia (USP) sets standards for all medical gases, including those that address quality, strength, purity, packaging, labeling, and identification. The proper handling of medical gases has been called into question during the past several years because of incidents resulting in patient harm and even death that have been documented by the US Food and Drug Administration, by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO), and by USP through its Medication Errors Reporting Program. In most cases, the deaths and injuries occurred to patients who were thought to be receiving medical-grade oxygen but instead were receiving a different gas (e.g., nitrogen or argon) that had been mistakenly connected to the oxygen supply system.

In April 2001, FDA issued a Public Health Advisory addressing the reports from hospitals and nursing homes concerning deaths and injuries to patients resulting from medical gas errors (1). In the advisory, FDA pointed out that incorrect gases were administered to patients who should have received oxygen. The advisory also described recurring errors caused by a lack of training of personnel who connected gas to the systems and who failed to carefully examine the labels on the gas containers. In response, FDA made several recommendations to help prevent future errors:

  • In hospitals and other patient-care facilities, medical-grade products should be stored separately from industrial-grade products.
  • All personnel who handle medical gases should be trained to recognize various types of medical gas labels and should be trained to examine labels carefully.
  • Personnel should understand how containers are connected to oxygen supply systems and be instructed about the serious consequences of changing or forcing connections.
  • Facilities should emphasize repeatedly that the fittings on medical gas containers should not be changed under any circumstances.
  • Once a cryogenic container is connected to an oxygen supply system and before the product is introduced into an air-supply system, a knowledgeable person should ensure that the correct container has been connected properly.

In 2001, the USP Medication Errors Reporting Program received a report from a community hospital indicating that mislabeled gas cylinders were delivered to the hospital. According to the report, four yellow air tanks with air tank fittings (valves) were delivered from the supplier and were mislabeled as nitrogen. An alert respiratory therapist recognized the distinctive air-tank fittings and alerted the appropriate personnel, thus preventing these mislabeled products from reaching patients. As a result of this error and others reported to FDA, USP posted an article on its Web site alerting practitioners about the possibility of medical gas mix-ups and cited the FDA Public Health Advisory (2).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here